Skip to main content
Clinical Trials/EUCTR2005-005122-31-ES
EUCTR2005-005122-31-ES
Active, Not Recruiting
Phase 1

Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg bolus of ivabradine followed by 8-hour infusion at the dose of 5 mg of ivabradine given after a percutaneous coronary intervention following a myocardial infarction with ST segment elevation

Institut de Recherches Internationales (for France)0 sites75 target enrollmentMarch 9, 2006

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Acute Myocardial Infarction
Sponsor
Institut de Recherches Internationales (for France)
Enrollment
75
Status
Active, Not Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 9, 2006
End Date
April 20, 2009
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Institut de Recherches Internationales (for France)

Eligibility Criteria

Inclusion Criteria

  • \- Male or female patients,
  • \- aged between 40 and 80 years (inclusive),
  • \- HR \> 80 bpm in sinus rythm,
  • \- patients who underwent a Percutaneous Coronary Intervention following an acute myocardial infarction with ST segment elevation.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \- Sick sinus syndrome;
  • \- second\-degree or third\-degree AV block;
  • \- trifascicular block and PR \> 240 ms;
  • \- hypertrophic cardiomyopathy, severe valvular disease, or severe congenital heart disease;
  • \- suspected aortic dissection;
  • \- known relevant electrolyte disorders.

Outcomes

Primary Outcomes

Not specified

Similar Trials